Clinical trials: Vinorelbine
Metastatic Breast Cancer
Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer
Development of an active second-line treatment option for metastatic breast cancer patients previously pre-treated with anthracyclines and taxanes in neoadjuvant, adjuvant or palliative settings.
- Trial name
- NCT04143906
- Testing
- Vinorelbine, Gemcitabine, Carboplatin
- Volunteers
- 200 people
- Sponsor
- Shandong Cancer Hospital and Institute
Breast Cancer
Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
This trial will compare the efficacy of sequential administration of Docetaxel, Carboplatin and Herceptin versus the administration of Vinorelbine and Herceptin combination as first line treatment in HER-2 positive patients with…
- Trial name
- NCT00453635
- Testing
- Docetaxel, Carboplatin, Herceptin
- Where
- 10 sites in Greece
- Volunteers
- 88 people
- Sponsor
- Hellenic Oncology Research Group
Neoplasms, Breast
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
This is an open-label, single-arm, multi-center, Phase II study to determine the activity of vinorelbine plus lapatinib in either first- or second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC).
- Trial name
- NCT00709618
- Testing
- Lapatinib, Vinorelbine
- Where
- 22 sites in United States
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Breast Cancer, Brain Metastases
A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER1, HER2 and HER4 receptors. This study is a single-arm, prospective, open label clinical study of pyrotinib plus vinorelbine as the therapy of brain metastases from…
- Trial name
- Pyrotinib (NCT03933982)
- Testing
- Pyrotinib Plus Vinorelbine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer, Metastasis, Neoplasm
Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)
The primary objective of this study is to evaluate the efficacy and tolerability of sequential use of vinorelbine and capecitabine as first line therapy in patients with MBC.
- Trial name
- NCT00629148
- Testing
- Vinorelbine and Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Esophageal Cancer, Gastric Cancer
Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma
The purpose of this study is to collect anti-tumor activity of vinorelbine when given to patients with esophageal or gastric tumors. We will also collect information on the toxicities of vinorelbine in these patients.
- Conditions
- Esophageal Cancer, Gastric Cancer, Stomach Cancer
- Trial name
- NCT00215462
- Testing
- Vinorelbine
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
BRMS1, Performance Status Zero to Two for Beginning the Study
Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.
Despite these initial positive signals in recent statistics, breast cancer continues to claim a substantial number of lives approximately 500,000 deaths worldwide in 2005 Thus the current treatment paradigm - surgery, radiation…
- Conditions
- BRMS1, Performance Status Zero to Two for Beginning the Study, Patient With a Maximum of One Chemotherapy, Patient With Progression After Taxanes
- Trial name
- GLICO-0801 (NCT01050322)
- Testing
- Lapatinib Vinorelbine, Lapatinib Capecitabine, Gemcitabine Lapatinib
- Where
- 18 sites in Argentina, Brazil and 1 more
- Volunteers
- 142 people
- Sponsor
- Latin American Cooperative Oncology Group